Summary of Key Information:
Reporting Period: Quarter ended June 30, 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting - Unaudited Financial Results
Audit Opinion:
Clean opinion - Limited Review Report states no material misstatements found in the unaudited financial results.
Key Financial Highlights [Amounts in ₹ Lakhs]:
Standalone Results:
Revenue from Operations: ₹10,203.18 lakhs
Total Income: ₹10,237.00 lakhs
Net Profit: ₹102.37 lakhs
EPS: ₹0.36 (Basic and Diluted)
Paid-up Equity Share Capital: ₹2,845.43 lakhs (Face Value ₹10 each)
Comparative Figures:
Previous Quarter (Q4 FY26):
- Revenue from Operations: ₹18,776.29 lakhs
- Total Income: ₹10,027.00 lakhs
- Net Profit: ₹137.13 lakhs
- EPS: ₹0.48
Previous Year Same Quarter (Q1 FY26):
- Revenue from Operations: ₹4,582.49 lakhs
- Total Income: ₹396.76 lakhs
- Net Profit: Not separately specified
- EPS: ₹1.39
Segment-wise Performance:
The company operates only in one segment: Manufacturing and Trading of Drugs & Pharmaceutical and all other allied activities revolving around the same. No separate segment reporting required under IND AS 108.
Corporate Actions:
Not Specified
Other Significant Information:
- Trading window closure: The trading window was closed and will reopen after 48 hours of results announcement
- The figures of previous year/periods have been regrouped wherever necessary
- Company has single business segment